Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.02, Zacks reports. The firm had revenue of $230 billion for the quarter, compared to analyst estimates of $0.18 million. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%.
Vistagen Therapeutics Stock Performance
Shares of NASDAQ VTGN traded up $0.12 during mid-day trading on Monday, hitting $2.97. 265,723 shares of the stock traded hands, compared to its average volume of 174,465. Vistagen Therapeutics has a 52 week low of $2.22 and a 52 week high of $5.74. The company has a market cap of $82.68 million, a price-to-earnings ratio of -2.40 and a beta of 0.77. The stock has a fifty day moving average price of $2.81 and a 200-day moving average price of $2.98.
Institutional Investors Weigh In On Vistagen Therapeutics
A hedge fund recently raised its stake in Vistagen Therapeutics stock. Bank of America Corp DE lifted its holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 1,068.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,141 shares of the company's stock after purchasing an additional 19,331 shares during the quarter. Bank of America Corp DE owned 0.08% of Vistagen Therapeutics worth $62,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 78.39% of the company's stock.
About Vistagen Therapeutics
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Read More
Before you consider Vistagen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vistagen Therapeutics wasn't on the list.
While Vistagen Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
